CRISPR Medicine News’ Post

* New: CMN Highlights * 𝗖𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗥𝗜𝗦𝗣𝗥 𝗼𝗳𝗳𝗲𝗿𝘀 𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗴𝗲𝗻𝗲 𝗻𝗲𝘁𝘄𝗼𝗿𝗸𝘀 Korean researchers have developed programmable conditional guide RNAs for precise control of endogenous gene expression using the CRISPR-Cas system. The new system, which has been demonstrated to work in E. coli, might have significant implications for human clinical applications. A significant challenge in synthetic biology is the regulation of gene networks rather than single genes. Traditional methods often struggle to control multiple genes simultaneously due to the complexity and interconnectivity of gene networks. This complexity can result in unpredictable behaviours and reduced efficiency in gene expression control. The precision required to manage multiple genes, especially within metabolic pathways, demands sophisticated tools that can integrate various signals and respond accurately, something that has proven difficult with existing technologies. The concept of logical operations, such as those found in digital electronics, offers a promising solution for the regulation of gene expression. By employing Boolean logic gates (AND, OR, NOT, and their combinations), researchers can create genetic circuits that perform complex decision-making processes based on multiple inputs. Logic gates allow for the conditional regulation of genes, providing a more robust and flexible approach to controlling biological systems. Logical operations enable the integration of diverse signals, facilitating precise control over gene networks and enhancing the ability to fine-tune cellular processes. Read all about how the cgRNAs were used at CRISPR Medicine News 👇 https://lnkd.in/dgX-QP4b #crisprmedicinenews #crisprmedicine #crispr #geneediting #crispractivation #dcas9 #geneticcircuits #syntheticbiology Hansol Kang Dongwon Park Jongmin Kim Pohang University of Science and Technology

Enjoy your weekly CRISPR Medicine News, where you can red about a novel compact epigenetic editor, CHARM, that might turn into a potential treatment for prion diseases. Have a great weekend 😎 🌞 https://lnkd.in/dCReqJmV #crisprmedicinenews #cmnweekly #crisprmedicine #crispr #geneediting Yale University Sidi Chen Whitehead Institute Broad Institute of MIT and Harvard Sonia Vallabh

#CRISPRMED25 Sponsor Update "We are excited to welcome a new Gold Sponsor of the 2nd CRISPR Medicine Conference, Copenhagen in April 7-11 2025, Vivlion GmbH - Vivlion will also be co-organising the Functional Genomics session" Stay tuned 👇 - the official CRISPRMED25 website will soon be live... https://lnkd.in/dKEjqb3j #crisprmed25 #crisprmedicine #crisprmedicinenews #crisprmed24

Meet the invited CRISPRMED25 Speakers: Keynote Speaker: Virginijus Siksnys, Prof., Ph.D., Head of Department, Vilnius University, Lithuania Jacob Giehm Mikkelsen Mikkelsen, Prof., Ph.D., Aarhus University, Denmark Annarita Miccio, Group Leader, Ph.D., Imagine Institute of Genetic Diseases, France Matthew Porteus, Prof., MD, Ph.D., Stanford Medicine, US Raffaella Di Micco, Group Leader, Ph.D., SR-TIGET, Italy Jacob Corn, Prof., Ph.D., ETH Zürich, Switzerland Gerald Schwank, Prof., Ph.D., University of Zürich, Switzerland Julian Grünewald, Ass. Prof., MD, Ph.D., Technical University of Munich, Germany William H. Peranteau, MD, Surgeon and Professor, University of Pennsylvania/Children’s Hospital of Philadelphia, US Guillermo Montoya, Prof., Research Director and Group Leader at the Protein Structure and Function program at CPR, University of Copenhagen, Denmark Kiana Aran, Associate Professor of Bioengineering and Medicine, University of California San Diego, US Rasmus O. Bak, Ass. Prof. and Group Leader, Aarhus University, Denmark Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden Ayal Hendel, Principal Investigator and Group Leader, Bar-Ilan University, Israel Alessia Cavazza, Ass. Prof., Group Leader, Infection, Immunity & Inflammation Department at University College London's Great Ormond Street Institute of Child Health, England Anna Cereseto, Prof., Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy Michael Jackson, Venture Capitalist ...

𝗖𝗥𝗜𝗦𝗣𝗥 𝗧𝗮𝗿𝗴𝗲𝘁𝘀 𝗣𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗖𝗮𝗻𝗰𝗲𝗿 𝗠𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝘀 Researchers have developed a selective CRISPR-Cas9 strategy to target somatic mutations in pancreatic cancer cells, which is showing promising results for precision cancer therapy. American researchers at the Johns Hopkins University School of Medicine adapted the CRISPR-Cas9 technology to specifically target somatic mutations that generate protospacer adjacent motifs (PAMs) within pancreatic cancer genomes. Whole genome sequencing of tumours and normal tissues from pancreatic cancer patients revealed numerous somatic PAMs, providing specific targets for CRISPR-induced double-strand breaks (DSBs). This selective targeting method resulted in significant cancer cell death with minimal off-target effects. The CRISPR approach involves the identification and utilisation of single base substitutions that create over 400 novel PAM sequences unique to the cancer cells. Researchers developed a bioinformatics pipeline named PAMfinder to pinpoint these mutations across the cancer genome. Learn how the CRISPR therapy fared in functional tests of cancer cell lines at CRISPR Medicine News 👇  https://lnkd.in/dSrgHwkc #crisprmedicinenews #crisprmedicine #crispr #geneediting The Johns Hopkins University School of Medicine Jim Eshleman Selina Shiqing Teh Kirsten Bowland, PhD

👁 𝐆𝐞𝐧𝐞-𝐄𝐝𝐢𝐭𝐢𝐧𝐠 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐑𝐞𝐭𝐢𝐧𝐚 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐖𝐨𝐫𝐥𝐝 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 2024 Earlier this month, CRISPR Medicine News attended Retina International World Congress 2024. The meeting, hosted by Irish patient-led charity Fighting Blindness, united individuals affected by retinal disease, caregivers, clinicians, researchers, patient advocates and genetics counsellors from all over the world. 🧬 Gene-editing highlights: Mark Pennesi (Oregon Health & Science University) presented a summary of the clinical data from Editas Medicine’s Phase 1/2 BRILLIANCE trial of EDIT-101 for the incurable disease Leber congenital amaurosis 10. Leah Byrne (University of Pittsburgh) presented in vivo models of PRPF31 retinitis pigmentosa (RP), which is one of the more prevalent forms of dominant RP. Read the summary from our chief editor here 👇🏻 https://lnkd.in/ek8-2X9f The image below shows Karen O'Hanlon Cohrt, PhD of CRISPR Medicine News (left) standing beside Ellen Moran, PhD of Fighting Blindness (right), standing in front of RIWC24 poster material at the Radisson Blu Royal Hotel, Dublin 8. #crisprmedicinenews #crisprmedicine #fightingblindness #riwc24 #geneediting #raredisease #blindness #retinaldisease

"The 3rd Copenhagen symposium on Advances in T cell therapy and Cellular engineering (CATC)" 24-25 September 2024. DTU, Kgs Lyngby, Denmark The Copenhagen Symposium on T Cell Therapy and Cellular Engineering (CATC) is a key event dedicated to exploring recent advancements in medical science. CATC brings together scientists, clinicians, and industry professionals to discuss the latest developments in T cell therapy and cellular engineering Organizing Committee: Özcan Met, Maria Ormhøj and Sine Reker Hadrup https://catc.dtu.dk/

𝘀𝗲𝗲𝗸𝗥𝗡𝗔 𝗗𝗶𝗿𝗲𝗰𝘁𝘀 𝗣𝗿𝗲𝗰𝗶𝘀𝗲 𝗚𝗲𝗻𝗲 𝗜𝗻𝘀𝗲𝗿𝘁𝗶𝗼𝗻 Researchers have developed a new method for precise target selection by using unusual type DEDD transposases. The method, seekRNA, is based on the IS1111 and IS110 insertion sequences and can be reprogrammed to target different sites. The study reveals that members of the IS1111 and IS110 insertion sequence (IS) families use a noncoding RNA (NCR)-derived seekRNA to guide target site selection during transposition. This seekRNA, which copurifies with the DEDD transposase, contains sequences complementary to both strands of the target site, essential for transposition. The seekRNA's configuration differs between the two families, indicating distinct mechanisms of target recognition. The researchers demonstrated the biotechnological potential of reprogramming the seekRNA and donor flank to target different sites, thereby enhancing gene-editing precision. Read more about seekRNA at CRISPR Medicine News 👇  https://lnkd.in/d_MakBdZ #crisprmedicinenews #crisprmedicine #crispr #geneediting  Sandro Ataide University of Sydney

𝗖𝗥𝗜𝗦𝗣𝗥 𝗜𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗲𝘀 𝗡𝗲𝘄 𝗚𝗲𝗻𝗲𝘀 𝗮𝘀 𝗗𝗿𝗶𝘃𝗲𝗿𝘀 𝗼𝗳 𝗣𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗖𝗮𝗻𝗰𝗲𝗿 𝗠𝗲𝘁𝗮𝘀𝘁𝗮𝘀𝗶𝘀  Three research groups recently independently elucidated the genetic and epigenetic mechanisms driving prostate cancer metastasis. The innovative use of CRISPR technology not only facilitated the discovery of the genes but also opened potential new avenues for targeted cancer therapies to prevent metastasis. CRISPR Medicine News interviewed Juan Martín Arriaga and Martin Kristian Thomsen who have made significant contributions to understanding the genetic drivers of prostate cancer metastasis using CRISPR technology. Arriaga's research identified CITED2 as a novel driver of bone metastasis in prostate cancer by conducting an in vivo genome-wide CRISPR screen. His team found that overexpressing CITED2 in the prostate led to metastasis, demonstrating its crucial role. Conversely, when CITED2 was inhibited, metastasis was suppressed. Thomsen's approach involved mutating specific tumour suppressor and epigenetic factor genes in a Cas9-positive mouse model, allowing for precise targeting within the prostate. His research revealed that mutations in the gene KMT2C were particularly significant for lung metastasis. We also dive into a third study by Maria Rodrigo-Faus who identified PRMT7 as crucial for prostate cancer metastasis. Read the full study at CRISPR Medicine News at https://lnkd.in/d8qQ3k6R #crispr #crisprmedicine #crisprmedicinenews #geneediting #prostatecancer #cancer #metastasis #metastatic Martin Thomsen Juan Arriaga Aarhus University Icahn School of Medicine at Mount Sinai Universidad Complutense de Madrid

𝐘𝐨𝐮𝐫 𝐰𝐞𝐞𝐤𝐥𝐲 𝐂𝐑𝐈𝐒𝐏𝐑 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐍𝐞𝐰𝐬 𝐢𝐬 𝐡𝐞𝐫𝐞! Enjoy the read and have a great weekend all! https://lnkd.in/dRdUhH2e #crisprmedicinenews #cmnweekly #crisprmedicine #crispr #geneediting